What patent date matters for Envarsus XR (and when does it expire)?
The key “patent expiry” date for Envarsus XR depends on which patent(s) you mean—there isn’t a single universal date for all forms of patent protection. Patent expiry can differ across jurisdictions and between patents covering the drug’s active ingredient, specific formulations, and any extended/exclusivity terms.
How to find the exact expiration date you’re looking for
To get the right expiry date, you need to match the patent to one of these common categories:
- Orange Book drug-product patents (typically formulation and method-of-use patents listed for the reference product)
- Orphan/non-patent exclusivities (if applicable)
- Patent terms adjusted/extended by the patent office (can move the effective expiry date)
If you mean the U.S. “Envarsus XR” reference product: what to check
In the U.S., the most practical way to determine when generic or biosimilar competition could be allowed is to check:
- the FDA Orange Book listings for Envarsus XR (which includes the listed patents and their expiration dates), and
- the exact patent numbers tied to the formulation/route of administration and any blocking patents.
Why the answer can vary by source
You may see different dates online because:
- different sources list different patents in the same portfolio,
- some dates reflect first scheduled expiry while others reflect adjusted/extended expiry, and
- filing and litigation events can delay or change entry timelines even after a patent expires.
What I need to give you the exact date
If you share either:
- the patent number(s) you’re seeing associated with Envarsus XR, or
- whether you mean U.S. (FDA Orange Book) versus another country,
I can tell you the precise expiration date tied to that specific patent entry.
Sources
No sources were provided in your prompt, so I can’t reliably cite the actual Envarsus XR patent expiration date.